• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

季节性流感疫苗的效果及mRNA疫苗的潜在益处。

Seasonal influenza vaccine performance and the potential benefits of mRNA vaccines.

作者信息

Russell Colin A, Fouchier Ron A M, Ghaswalla Parinaz, Park Yoonyoung, Vicic Nevena, Ananworanich Jintanat, Nachbagauer Raffael, Rudin Deborah

机构信息

Department of Medical Microbiology & Infection Prevention, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands.

出版信息

Hum Vaccin Immunother. 2024 Dec 31;20(1):2336357. doi: 10.1080/21645515.2024.2336357. Epub 2024 Apr 15.

DOI:10.1080/21645515.2024.2336357
PMID:38619079
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11020595/
Abstract

Influenza remains a public health threat, partly due to suboptimal effectiveness of vaccines. One factor impacting vaccine effectiveness is strain mismatch, occurring when vaccines no longer match circulating strains due to antigenic drift or the incorporation of inadvertent (eg, egg-adaptive) mutations during vaccine manufacturing. In this review, we summarize the evidence for antigenic drift of circulating viruses and/or egg-adaptive mutations occurring in vaccine strains during the 2011-2020 influenza seasons. Evidence suggests that antigenic drift led to vaccine mismatch during four seasons and that egg-adaptive mutations caused vaccine mismatch during six seasons. These findings highlight the need for alternative vaccine development platforms. Recently, vaccines based on mRNA technology have demonstrated efficacy against SARS-CoV-2 and respiratory syncytial virus and are under clinical evaluation for seasonal influenza. We discuss the potential for mRNA vaccines to address strain mismatch, as well as new multi-component strategies using the mRNA platform to improve vaccine effectiveness.

摘要

流感仍然是一种公共卫生威胁,部分原因是疫苗的有效性欠佳。影响疫苗有效性的一个因素是毒株不匹配,即由于抗原漂移或疫苗生产过程中出现意外(如适应鸡胚)突变导致疫苗与流行毒株不再匹配。在本综述中,我们总结了2011 - 2020年流感季节期间流行病毒的抗原漂移和/或疫苗毒株中出现的适应鸡胚突变的证据。有证据表明,在四个季节中抗原漂移导致了疫苗不匹配,在六个季节中适应鸡胚突变导致了疫苗不匹配。这些发现凸显了开发替代疫苗平台的必要性。最近,基于mRNA技术的疫苗已证明对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)和呼吸道合胞病毒有效,并且正在进行季节性流感的临床评估。我们讨论了mRNA疫苗解决毒株不匹配问题的潜力,以及使用mRNA平台提高疫苗有效性的新的多组分策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6dc/11020595/d24905be7a95/KHVI_A_2336357_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6dc/11020595/4924e106281a/KHVI_A_2336357_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6dc/11020595/d24905be7a95/KHVI_A_2336357_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6dc/11020595/4924e106281a/KHVI_A_2336357_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6dc/11020595/d24905be7a95/KHVI_A_2336357_F0002_OC.jpg

相似文献

1
Seasonal influenza vaccine performance and the potential benefits of mRNA vaccines.季节性流感疫苗的效果及mRNA疫苗的潜在益处。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2336357. doi: 10.1080/21645515.2024.2336357. Epub 2024 Apr 15.
2
Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses.2012 - 13年度流感疫苗效力较低与鸡蛋适应性H3N2疫苗株的突变有关,而非与流行病毒中的抗原漂移有关。
PLoS One. 2014 Mar 25;9(3):e92153. doi: 10.1371/journal.pone.0092153. eCollection 2014.
3
Antigenic Drift of A/H3N2/Virus and Circulation of Influenza-Like Viruses During the 2014/2015 Influenza Season in Poland.2014/2015流感季节波兰A/H3N2病毒的抗原漂移及类流感病毒的传播情况
Adv Exp Med Biol. 2016;905:33-8. doi: 10.1007/5584_2016_216.
4
Frequent Genetic Mismatch between Vaccine Strains and Circulating Seasonal Influenza Viruses, Hong Kong, China, 1996-2012.1996-2012 年中国香港地区疫苗株与季节性流感病毒间频繁的基因错配。
Emerg Infect Dis. 2018 Oct;24(10):1825-1834. doi: 10.3201/eid2410.180652.
5
A decavalent composite mRNA vaccine against both influenza and COVID-19.一种针对流感和 COVID-19 的十价复合 mRNA 疫苗。
mBio. 2024 Sep 11;15(9):e0066824. doi: 10.1128/mbio.00668-24. Epub 2024 Aug 6.
6
Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: An updated systematic review and meta-analysis.高剂量流感疫苗对老年人的疗效和效果与循环株和抗原匹配的关系:一项更新的系统评价和荟萃分析。
Vaccine. 2021 Mar 15;39 Suppl 1:A24-A35. doi: 10.1016/j.vaccine.2020.09.004. Epub 2021 Jan 7.
7
Comparison of A(H3N2) Neutralizing Antibody Responses Elicited by 2018-2019 Season Quadrivalent Influenza Vaccines Derived from Eggs, Cells, and Recombinant Hemagglutinin.比较 2018-2019 季节来源于鸡蛋、细胞和重组血凝素的四价流感疫苗诱导的 A(H3N2)中和抗体反应。
Clin Infect Dis. 2021 Dec 6;73(11):e4312-e4320. doi: 10.1093/cid/ciaa1352.
8
Nucleoside-Modified mRNA-Based Influenza Vaccines Circumvent Problems Associated with H3N2 Vaccine Strain Egg Adaptation.基于核苷修饰的 mRNA 的流感疫苗规避了与 H3N2 疫苗株在鸡蛋中适应相关的问题。
J Virol. 2023 Jan 31;97(1):e0172322. doi: 10.1128/jvi.01723-22. Epub 2022 Dec 19.
9
Contribution of Neuraminidase to the Efficacy of Seasonal Split Influenza Vaccines in the Ferret Model.神经氨酸酶对季节性流感疫苗在雪貂模型中的疗效的贡献。
J Virol. 2022 Mar 23;96(6):e0195921. doi: 10.1128/jvi.01959-21. Epub 2022 Feb 2.
10
Directed selection of influenza virus produces antigenic variants that match circulating human virus isolates and escape from vaccine-mediated immune protection.对流感病毒进行定向选择会产生与正在传播的人类病毒分离株相匹配的抗原变异体,并逃避疫苗介导的免疫保护。
Immunology. 2016 Jun;148(2):160-73. doi: 10.1111/imm.12594. Epub 2016 Mar 30.

引用本文的文献

1
Genetic Evolution of the Hemagglutinin Genes of Seasonal Influenza A Viruses in Türkiye Between 2017 and 2023.2017年至2023年土耳其季节性甲型流感病毒血凝素基因的遗传进化
Influenza Other Respir Viruses. 2025 Jul;19(7):e70134. doi: 10.1111/irv.70134.
2
Molecular Evolution of Influenza A Viruses From Mauritius, 2017-2019.2017 - 2019年毛里求斯甲型流感病毒的分子进化
Influenza Other Respir Viruses. 2025 May;19(5):e70108. doi: 10.1111/irv.70108.
3
Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults ≥50 Years: A Randomized Clinical Trial.

本文引用的文献

1
Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults.基于 mRNA 的 RSV 前体疫苗在老年人中的疗效和安全性。
N Engl J Med. 2023 Dec 14;389(24):2233-2244. doi: 10.1056/NEJMoa2307079.
2
Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis.一种基于 mRNA 的四价季节性流感疫苗(mRNA-1010)在健康成年人中进行的 1/2 期随机临床试验的安全性和免疫原性:中期分析。
Nat Commun. 2023 Jun 19;14(1):3631. doi: 10.1038/s41467-023-39376-7.
3
An mRNA Influenza Vaccine - Could It Deliver?
≥50岁成人流感与新冠多组分疫苗的免疫原性和安全性:一项随机临床试验
JAMA. 2025 May 7. doi: 10.1001/jama.2025.5646.
4
An mRNA-based seasonal influenza vaccine in adults: Results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibition titers.一种用于成人的基于信使核糖核酸的季节性流感疫苗:两项3期随机临床试验结果及血凝抑制滴度的保护相关性分析
Hum Vaccin Immunother. 2025 Dec;21(1):2484088. doi: 10.1080/21645515.2025.2484088. Epub 2025 Apr 2.
5
Comprehensive Analysis of Influenza Viruses' Trends in Italy: Insights from a Nationwide and Regional Perspective.意大利流感病毒趋势的综合分析:来自全国和地区视角的见解
Infect Dis Rep. 2025 Feb 27;17(2):20. doi: 10.3390/idr17020020.
6
Reduced risks of influenza-associated hospitalization and complications following vaccination among over 2 million older individuals: a nationwide study using target trial emulation framework.超过200万老年人接种疫苗后,与流感相关的住院和并发症风险降低:一项使用目标试验模拟框架的全国性研究
BMC Med. 2025 Mar 13;23(1):157. doi: 10.1186/s12916-025-03955-w.
7
[Platform technologies in vaccine development].[疫苗研发中的平台技术]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2025 Apr;68(4):368-377. doi: 10.1007/s00103-025-04024-6. Epub 2025 Mar 4.
8
Effectiveness of inactivated influenza vaccine against laboratory-confirmed influenza in elderly Chinese patients with diabetes: A test-negative design case-control study.灭活流感疫苗对中国老年糖尿病患者实验室确诊流感的有效性:一项检验阴性设计的病例对照研究。
Hum Vaccin Immunother. 2025 Dec;21(1):2458814. doi: 10.1080/21645515.2025.2458814. Epub 2025 Jan 30.
9
Advantages of Broad-Spectrum Influenza mRNA Vaccines and Their Impact on Pulmonary Influenza.广谱流感mRNA疫苗的优势及其对肺部流感的影响。
Vaccines (Basel). 2024 Dec 7;12(12):1382. doi: 10.3390/vaccines12121382.
10
Adverse reactions to mRNA COVID-19 vaccine in people with allergies in Japan.日本过敏人群对新冠mRNA疫苗的不良反应。
Glob Health Med. 2024 Dec 31;6(6):363-374. doi: 10.35772/ghm.2024.01053.
一种mRNA流感疫苗——它能成功吗?
N Engl J Med. 2023 Mar 23;388(12):1139-1141. doi: 10.1056/NEJMcibr2215281.
4
Vaccine effectiveness of recombinant and standard dose influenza vaccines against outpatient illness during 2018-2019 and 2019-2020 calculated using a retrospective test-negative design.使用回顾性病例对照设计计算 2018-2019 年和 2019-2020 年重组和标准剂量流感疫苗对门诊疾病的疫苗有效性。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2177461. doi: 10.1080/21645515.2023.2177461. Epub 2023 Feb 21.
5
Global and national influenza-associated hospitalisation rates: Estimates for 40 countries and administrative regions.全球和国家流感相关住院率:40 个国家和行政区的估计值。
J Glob Health. 2023 Jan 27;13:04003. doi: 10.7189/jogh.13.04003.
6
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022.二价 mRNA 疫苗预防有症状的 SARS-CoV-2 感染的效果-增加社区获得检测的项目,美国,2022 年 9 月至 11 月。
MMWR Morb Mortal Wkly Rep. 2022 Dec 2;71(48):1526-1530. doi: 10.15585/mmwr.mm7148e1.
7
A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes.一种针对所有已知流感病毒亚型的多价核苷修饰 mRNA 疫苗。
Science. 2022 Nov 25;378(6622):899-904. doi: 10.1126/science.abm0271. Epub 2022 Nov 24.
8
Has influenza B/Yamagata become extinct and what implications might this have for quadrivalent influenza vaccines?乙型/Yamagata 流感是否已经灭绝,这对四价流感疫苗可能意味着什么?
Euro Surveill. 2022 Sep;27(39). doi: 10.2807/1560-7917.ES.2022.27.39.2200753.
9
Does repeated influenza vaccination attenuate effectiveness? A systematic review and meta-analysis.重复接种流感疫苗会降低其效果吗?系统评价和荟萃分析。
Lancet Respir Med. 2023 Jan;11(1):27-44. doi: 10.1016/S2213-2600(22)00266-1. Epub 2022 Sep 21.
10
A Bivalent Omicron-Containing Booster Vaccine against Covid-19.二价含奥密克戎成分的新冠病毒加强疫苗。
N Engl J Med. 2022 Oct 6;387(14):1279-1291. doi: 10.1056/NEJMoa2208343. Epub 2022 Sep 16.